In order to investigate the therapeutic utility of ALK TKIs and miR-1304-5p in NB, cells were transfected with miR-1304-5p mimics prior to ALK TKI treatment, which significantly decreased the ED50s for both brigatinib and ceritinib in MYCN non-amplified SH-SY5Y (p = 0.0047 and p = 0.0042, respectively; Fig. 4A, B), MYCN amplified KELLY (p = 0.0038 and p = 0.0002, respectively; Fig. 4C, D) and MYCN non-amplified ALK wild type LA-N-6 cells (Supplementary Fig. 10A, B). This evidence concerns the gene MYCN and neuroblastoma.